Praxis Precision Medicines, Inc. · NASDAQ:PRAX
Praxis Precision Medicines — Investor Day (November 2026)
132 slides from Praxis Precision Medicines's investor day presentation, Nov 12, 2026
Slide 1: Investor Day November 12, 2026 – New York City
Investor Day November 12, 2026 – New York City
Slide 2: Forward-looking statements
2 This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, relating to our business, operations, and financial conditions, including but not limited to express or implied statements regard
Slide 3: Takeaways For Today
3 Takeaways For Today 01 Ready to execute commercially at the highest level With • Proven leadership • State-of-the-art infrastructure • Capital to execute at full force 02 Poised to become the preeminent neurology company in the world No other company will match our • Breadth of impact • Depth of p
Slide 4: Praxis' Mission
4 The needs of patients with CNS disorders are devastatingly urgent. Our mission is to help patients by delivering life-altering treatments faster and more effectively than has ever been done before — and to do it again and again. PRAXIS’ MISSION
Slide 5: What It Takes to Do It Again and Again
5 What It Takes to Do It Again and Again PRAX daily closing share price, $ (split-adjusted) $100 $200 $300 $400 $0 2025 2026 2027 2028 2029 2030 D E F I N I N G T R A I T S T H A T W I L L C A R R Y U S F O R W A R D Focus Resilience Conviction Accountability Again and again. Source: FactSet daily c
Slide 6: Praxis' Full Pipeline Today
6 Praxis’ Full Pipeline Today DEE: developmental and epileptic encephalopathy; FOS: focal onset seizures; LoF: loss of function; ATM: Ataxia-telangiectasia. MARKETED C E R E B R U M S O L ID U S Essential tremor Ulixacaltamide Parkinson's disease PRAX-051 CaV3.x-selective inhibitor PRAX-050 Pan-CaV3
Slide 7: 2035 Vision: Two Platforms Treating Diseases Across Four Franchises
7 2035 Vision: Two Platforms Treating Diseases Across Four Franchises Illustrative scenario. DEE: developmental and epileptic encephalopathy; LoF: loss of function; ATM: Ataxia-telangiectasia. Epilepsy Movement Disorders Neuro- development Pain Relutrigine SCN2A & SCN8A DEE Relutrigine Broad DEEs Vo
Slide 8: Consensus Will Push Praxis to the Top Neurology Portfolio
8 As Each of Our Late-Stage Assets Is Approved, Consensus Will Push Praxis to the Top Neurology Portfolio Analyst Consensus Sales ($B) $5B $10B $15B 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E $3.7 $3.9 $4.5 $4.4 $5.1 $5.4 $5.6 $10.5 $9.7 $10.6 $13.1 $13.5B 2035E consensus assuming approva
Slide 9: Commercial Excellence Coupled with a Rapidly Advancing Pipeline
9 Commitment to Commercial Excellence Coupled with a Rapidly Advancing Pipeline $13.1 $10.6 $9.7 $10.5 $5.6 $5.4 $5.1 $4.4$4.5 $3.9 $3.7Ulixacaltamide $10.0 (+$2.3) Relutrigine $5.0 (+$1.7) Vormatrigine $4.0 (+$2.2) Elsunersen $1.0 (+$0.3) $20B+ Praxis peak sales guidance + pipeline Source: Bloomber
Slide 10: Agenda
10 Agenda Marcio Souza President and CEO Megan Sniecinski Chief Operating Officer Steve Petrou President of R&D Erik Johnson Head of Commercial John Bullock Head of Sales Ulixacaltamide Essential tremor • Unmet need • Clinical data • Commercial strategy • KOL panel Dr. William Ondo Dr. Daniel Kremen
Slide 11: Two First Launches. A Growing Portfolio
Two First Launches. A Growing Portfolio Ulixacaltamide and Relutrigine Anchor a Commercial Engine Built for Many Ulixacaltamide Relutrigine
Slide 12: A First-Principles, Disciplined Approach to Commercialization
12 A First-Principles, Disciplined Approach to Commercialization Built to Repeat Build Exceptional TEAMS Build teams committed to our mindset, operating model and excellence standard Customize the EXPERIENCE Provide solutions so patients and physicians can focus on outcomes. Execute With INSIGHT Com
Slide 13: Investing Upfront to Accelerate Patient Impact
13 Maximizing Long-Term Value by Investing Upfront to Accelerate Patient Impact THE INVESTMENT WHAT IT FUNDS WHY WE DO IT MAXIMIZED FIELD FORCE Full teams in place ahead of launch with full target coverage and dynamic capacity vs. typical incremental build End-to-end oversight of the entire patient
Slide 14: Build and Deploy Dedicated Teams Ahead of Launch
14 Rigorous and Disciplined Approach to Build and Deploy Dedicated Teams Ahead of Launch HIRING Sequenced hiring enabled direct leaders to recruit and hire next-level Track record of exceptional performance TRAINING Shift from Module-to-Test to an Innovative Learning and Engagement Model 1 AI
Slide 15: Maximum Value for all Stakeholders is the Core Launch Priority
15 Achieving Maximum Value for all Stakeholders is the Core Launch Priority Typical LaunchPrioritize Quantity Prioritize Quality ULIXACALTAMIDE - ET A Strong First Experience RELUTRIGINE - SCN2A/8A DEE Treatment Paradigm Shift Launch progress CUSTOMIZE THE EXPERIENCE
Slide 16: State-of-the-Art Infrastructure Integrates Real-Time Data
16 State-of-the-Art Infrastructure Integrates Real-Time Data to Monitor Actionable Insights and Launch Execution DATA INPUTS DATA USES Digital Rx Platform Patient Services Field CRM Marketing SP Channel Formulary Claims Medical Information Pharmacovigilance + 20 more platforms PATIENT/PHYSICIAN SUPP
Slide 17: The Hub of the Future
17 The Hub of the Future Fully Integrates Rx Writing, Patient Services and Specialty Pharmacy, Tailored to Each Market CUSTOMIZE THE EXPERIENCE Digital Prescription Intake Specialty Pharmacy Distribution Office & Patient Support 1 PRESCRIBE Prescribe from the EHR 2 GET ACCESS Coverage answered fast
Slide 18: Two Launches. First of Their Kind.
18 Two Launches. First of Their Kind. D A R I N G F O R M O R E Dec 27, 2026 Relutrigine SCN2A & SCN8A Developmental and Epileptic Encephalopathy Jan 29, 2027 Ulixacaltamide Essential Tremor
Slide 19: Ulixacaltamide: Essential Tremor
19 E S S E N T I A L T R E M O R Ulixacaltamide The first medicine designed for essential tremor Jan 29, 2027 PDUFA date
Slide 20: Essential Tremor Is the Sleeping Giant of Neurology
20 Essential Tremor Is the Sleeping Giant of Neurology: Common, Disabling and Ready for Change Sources: Louis ED, Ottman R. Tremor Other Hyperkinet Mov (N Y). 2014;4:259; Louis ED, et al. Parkinsonism Relat Disord. 2015;21(7):729-735; Louis ED, et al. Eur J Neurol. 2007;14(10):1138-46; Elble RJ. Cur
Slide 21: ET Severely Limits Patients' Ability to Function
21 ET Severely Limits Patients' Ability to Function Source: Praxis data on file, ET patient survey, Mar/Apr 2026 Speaking 16% Everyday activities affected by ET, % of patients Patients could select multiple activities Writing 86% Eating with a spoon 76% Drinking from a cup 73% Household and hobbies
Slide 22: An Aging US Demographic Drives ET Growth
22 An Aging US Demographic Drives ET Growth Faster Than the Overall Population Each dot ≈ 100K people. Sources: 2012: Louis ED, Ottman R. Tremor Other Hyperkinet Mov. 2014;4:259; US Census Bureau intercensal estimates 2010–2020 and 2023 National Population Projections (middle series). 2026 and 2040
Slide 23: Poor Standard of Care Keeps Patients From Seeking Treatment
23 Today, a Poor Standard of Care Keeps Patients From Seeking Treatment Each dot ≈ 100K patients. Source: Diagnosis rate: Louis and Ottman (2014), Crawford et al. (2020); Treatment rate: Diaz & Louis (2010); Internal claims analysis; Familial History based on Ph2, Ph3, and patient survey data ~9M Li
Slide 24: Observational Study Reinforces That Current ET Care Falls Short
24 Findings From an Observational Study Reinforce That Current ET Care Falls Short ET patients under care confirmed with active claims, linked to MD NPI: Medical Doctor National Provider Identifier Source: Praxis HCP observational quant study, 2026. W H O W A S S T U D I E D >2,300 US physicians >43
Slide 25: ESSENTIAL3: First Positive Phase 3 Program in Essential Tremor
25 U L I X A C A L T A M I D E ESSENTIAL3: First Positive Phase 3 Program in Essential Tremor Steve Petrou
Slide 26: ESSENTIAL3 Program Design
26 ESSENTIAL3: Innovative Program Designed to Demonstrate Ulixacaltamide Restores and Maintains Patient Function Stable responders defined as those who met the prespecified 3-pt improvement in the mADL11 during the blinded lead-in. STUDY 1 · PLACEBO-CONTROLLED PARALLEL GROUP R 1:1 Ulixacaltamide Pla
Slide 27: ESSENTIAL3 Baseline Demographics
27 ESSENTIAL3 Baseline Demographics Illustrate Functional Disability and Disease Burden Ranked by share scoring 3–4. TETRAS-ADL = Essential Tremor Rating Assessment Scale – Activities of Daily Living. Source: Farmer et al. AAN 2026 Plenary Presentation; Praxis Data on File Baseline TETRAS-ADL score
Slide 28: Clinical Program Solidifies Core Strengths of Ulixacaltamide
28 STUDY 2 · RANDOMIZED WITHDRAWAL Clinical Program Solidifies Core Strengths of Ulixacaltamide -4.3 -1.7 p < 0.0001 ULIXACALTAMIDE (n=199) PLACEBO (n=233) 55% 33% p = 0.037 ULIXACALTAMIDE (n=40) PLACEBO (n=40) Primary endpoint met Primary endpoint met mADL11: modified ADL 11-item score, CFB: change
Slide 29: Rapid Onset of Effect by Day 14
29 Rapid Onset of Effect Experienced by First Assessment (Day 14) Source: Shtilbans et al. AAN 2026 Poster Within 14 days patients saw significant improvement in their disease Rapid Maintained Deep Consistent Robust TETRAS-ADL change from baseline LS mean, points Placebo Study 2 Study 1 -7 -6 -5 -4
Slide 30: Large Benefit Across Stringent Response Thresholds
30 Large Benefit Maintained Across 12 Weeks Across Stringent Response Thresholds MCID = minimum clinically important difference (−1.25 mADL11 points). ROC: receiver operating characteristic. Error bars are 95% CI. Source: Farmer et al. AAN 2026 Plenary Presentation Rapid Maintained Deep Consistent R
Slide 31: Maintenance of Response After Switch to Placebo
31 Maintenance of Response and Pharmacological Response is Further Confirmed After Patients Switched to Placebo mADL11: modified 11-item TETRAS-ADL score; CGI-S: Clinical Global Impression of Severity; PGI-S: Patient Global Impression of Severity; PGI-C: Patient Global Impression of Change. Net % ch
Slide 32: Effect Maintained Over Years
32 Effect of Ulixacaltamide Treatment is Maintained Over Years, Despite ET’s Progressive Course Essential3 Protocol amended to add TETRAS-ADL Assessment in Study 3 Long Term Safety Study (LTSS); Collection began November 2026 and is ongoing for participants in Study 3 who completed Study 1 or Study
Slide 33: Significant Gains in Daily Functioning
33 Patients Experienced Significant Gains in Daily Functioning Treatment difference p < 0.01 at all responder thresholds (logistic regression). Source: Shtilbans et al. AAN 2026 Poster Patients reaching Responder TETRAS-ADL Thresholds at Day 56 % of ulixacaltamide patients combined Study 1 and Study
Slide 34: Consistent Across Multiple Endpoints and Subgroups
34 Results Were Consistent Across Multiple Endpoints and Subgroups From Two Independent Studies PGI-C: Patient Global Impression of Change; CGI-S: Clinical Global Impression of Severity. Source: Shtilbans et al. AAN 2026 Poster 0% 20% 40% 60% Placebo Study 1 Study 2 0% 20% 40% 60% Placebo Study 1 St
Slide 35: Primary Benefit Robust to Sensitivity Analysis
35 Primary Benefit is Robust to Sensitivity Analysis MMRM (MAR) included baseline mADL11, treatment, categorical visit, treatment-by-visit interaction, and randomization strata, with unstructured covariance. MAR MI, copy-reference (CR), and tipping-point analyses each used 100 multiply imputed datas
Slide 36: Ulixacaltamide Delivers Compelling Efficacy Profile
36 Ulixacaltamide Delivers Compelling Efficacy Profile Rapid Day 14 ~5 points gained in ADL at the first assessment Maintained 95 weeks benefit held through Day 84 and 95 weeks; lost when switched to placebo Deep ~1 in 5 patients improved 12 or more TETRAS-ADL points Consistent Multiple Endpoints co
Slide 37: Ulixacaltamide Commercialization Strategy
37 U L I X A C A L T A M I D E Commercialization Strategy Erik Johnson
Slide 38: The Sleeping Giant is Ready to be Awakened
38 The Sleeping Giant is Ready to be Awakened with The First Targeted Drug Therapy Abbreviations: DSE, disease state education; DTC, direct-to-consumer; NP/PA, nurse practitioner/physician assistant; PA, prior authorization. M A R K E T D Y N A M I C S Highly prevalent disease Dormant market with li
Slide 39: HCPs Aligned With Ulixacaltamide Profile
39 HCPs are Naturally Aligned With the Profile of Ulixacaltamide Source: HCP observational quant study, March 2026 (N = 2,303 US physicians treating ET). 0% 0% 1% 8% 21% 33% 36% 1 2 3 4 5 6 7 0% 1% 3% 11% 25% 35% 25% 1 2 3 4 5 6 7 90% Regaining one function is meaningful (e.g. brushing teeth, pourin
Slide 40: HCPs View Ulixacaltamide Favorably
40 HCPs View Ulixacaltamide Favorably and are Motivated to Prescribe to their ET Patients Source: HCP observational quant study, March 2026 (N = 2,303 US physicians treating ET). 0% 1% 2% 9% 35% 42% 12% 1 2 3 4 5 6 7 88% rate ulixacaltamide’s overall profile as favorable 1 = unfavorable · 7 = favora
Slide 41: ESSENTIAL TO MET DSE Campaign
41 The ESSENTIAL TO METM DSE Campaign has been Successful in Driving Confidence to Treat and Empowering Patients to Seek Care HCPs will recognize: ET as a serious disease warranting active treatment The importance of ADL-based functional improvement The importance of proper use of ICD-10 G25.0
Slide 42: DTC Will Further Mobilize the Market at Launch
42 DTC Will Further Mobilize the Market at Launch FOR INITIAL LAUNCH FOR LONG-TERM Drives Awareness • Empowers patients to raise ET with their HCP now Engages Undertreated & Discontinued Patients • Reframes ET as actionable and treatable Addresses ET Underdiagnosis • A new treatment drives reason fo
Slide 43: Support From First Prescription Through Maintenance
43 With Neurologists Ready to Treat, Praxis Adds Support From the First Prescription Through Maintenance THE NEUROLOGIST PERSPECTIVE Strong enthusiasm for the profile Rapid onset Once-daily dosing Adjunctive to current ET meds CONVERSATION BEFORE THE FIRST PATIENT A Praxis conversation with each phy
Slide 44: The Hub of the Future
44 The Hub of the Future Fully Integrates the Rx Writing, Patient Services and Specialty Pharmacy Abbreviations: EHR, electronic health record. BI/BV benefits investigation/benefits verification 1 PRESCRIBE Prescribe from the EHR The prescription goes straight from the EHR with required info 2 GET A
Slide 45: Supply and Distribution Built Ahead of Approval
45 Praxis Has Built Supply and Distribution Ahead of Approval so Patients Get Ulixacaltamide From Day One Specialty Pharmacy Network Product Supply CDMO Network 3PL Patient S U P P L Y I N V E S T M E N T A N D P R E P A R E D N E S S A L I G N T O P A Y E R - O W N E D P H A R M A C I E S Proactive
Slide 46: Price Corridor Captures Value While Maintaining Access
46 Price Corridor Captures Value While Maintaining Access Gross annual price for selected analogs; not to scale. Austedo: WAC $5,278.17/60 × 6 mg tablets, $5,937.96/60 × 9 mg tablets and $7,917.14/60 × 12 mg tablets. Ingrezza: WAC $9,072/30 × 80 mg capsules. Nuplazid: WAC $5,120/30 × 34 mg capsules.
Slide 47: Every Point of Penetration Generates Blockbuster Sales
47 The Scale of Unmet Need in ET Means Every Point of Penetration Generates Blockbuster Sales ILLUSTRATIVE SALES MATH 2M ET patients seeking treatment today × 1% penetration × $50K annual net price = $1B annual revenue Source: Internal claims analysis
Slide 48: The Opportunity is Vast
48 The Opportunity is Vast, and Our Launch is Built to Match It Illustrative. Peak sales = 2M ET patients seeking treatment × penetration × $50K annual net price. Avg. analyst model: mean peak patients on drug across sell-side models ÷ 2M. HCP study: mean % of ET patients physicians would prescribe
Slide 49: Ulixacaltamide: Activating Demand and Pull Through
49 U L I X A C A L T A M I D E Activating Demand and Pull Through John Bullock
Slide 50: Precision Targeting of Physicians Who Matter Most
50 Precision Targeting Puts Our Field Team in Front of the Physicians Who Matter Most – Driving Impact S T E P 1 Identify diagnosed ET patients Through diagnosis and Rx claims S T E P 2 Map to their physicians All specialties identified for each patient S T E P 3 Rank on ET impact Based on factors s
Slide 51: ~300 Field Team Covers Every Key ET Prescriber
51 Every Key ET Prescriber Is Covered by a ~300 Field Team with Capacity for Dynamic Targeting ~19K WHO WE CALL ON target HCPs, where ET patient volume and influence are concentrated = 13 - 15K Neurologists Top-tier neurologists, including movement disorder specialists 4.5 - 5.5K PCPs High-volume, h
Slide 52: Offices Are Ready Before the First Patient Asks
52 Offices Are Ready Before the First Patient Asks: Educated, Prepared and Connected PRE-APPROVAL DISEASE EDUCATION OFFICE OPERATIONS HCP EDUCATION First new ET therapy in decades; data consistent with label READINESS FOR PATIENT DIALOGUE Set expectations for rapid onset and possible common side eff
Slide 53: High-Touch Experience Supports Initiation and Adherence
53 A High-Touch Experience Supports Initiation, Maintenance and Adherence 1 WELCOME Set expectations Pharmacist call covers the disease, product and side effects to expect 2 EARLY TITRATION Manage tolerability Nurse or pharmacist check-ins 3 DOSE PROGRESSION Confirm readiness Confirm the patient is
Slide 54: Broad Ulixacaltamide Coverage Expected
54 Broad Ulixacaltamide Coverage Expected with a Predictable Path to Treatment OUR ACCESS OBJECTIVE Broad coverage aligned with the anticipated label Launch 3-6 months Ongoing Launch and early access As payer policies develop ~65% Medicare Part D Formulary exception requests available at launch; app
Slide 55: A Large Market, the Right Drug and a Launch Built to Win
55 01 A large and growing market 02 A therapy patients need and physicians want 03 The people, systems and strategy to deliver A Large Market, the Right Drug and a Launch Built to Win
Slide 56: Relutrigine: Developmental & Epileptic Encephalopathies
56 D E V E L O P M E N T A L & E P I L E P T I C E N C E P H A L O P A T H I E S Relutrigine First medicine designed for SCN2A and SCN8A DEEs Dec 27, 2026 PDUFA date
Slide 57: Sodium Channels are Key in Seizure Activity in DEEs
57 Sodium Channels are Key in Seizure Activity in DEEs Illustrative. Scheffer et al. Nat Rev Dis Primers. 2024; Wengert et al. J Neurosci. 2021; Guerrini et al. Physiol Rev. 2023; Berecki et al. PNAS. 2018. Abbreviations: AP, action potential; DEE, developmental and epileptic encephalopathy; NaV, vo
Slide 58: Children and Families Face Severe Disease Burden
58 Children and Families Face Severe Disease Burden Living with SCN2A and SCN8A DEEs Photos shared at Praxis 2024 DEEP Dive Day. Sources: Zuberi SM, et al. Epilepsia. 2022; Gallop K, et al. Epilepsy Behav. 2021; Thurman DJ, et al. Epilepsia. 2014; CHOP SCN2A-related disorders. No medicine has ever b
Slide 59: Relutrigine: EMBOLD First Study
59 R E L U T R I G I N E EMBOLD: First Study Ever Done For SCN2A and SCN8A DEE Patients Steve Petrou
Slide 60: EMBOLD Enrolled a Severe Population
60 EMBOLD Enrolled a Severe Population of SCN2A/8A Patients ASM=antiseizure medication; OLE=open-label extension. Source: Kamireddy et al. AES 2025; Frizzo et al. IEC 2025; NCT05818553 PATIENT PROFILE Heavily pre-treated pediatric SCN2A/SCN8A population ASMs at baseline: ~1/3 1–2 ASMs ~2/3 3–6 ASMs
Slide 61: Significant Seizure Reduction in EMBOLD
61 Significant Seizure Reduction in the EMBOLD Study Primary endpoint: placebo-adjusted change in monthly (28-day) motor seizure frequency, Cohort 2. Primary analysis used NB1 regression, adjusted for baseline motor-seizure rate and treatment-evaluable days. Relutrigine periods from both randomized
Slide 62: Seizure Reduction Deepening Over Time
62 Unprecedented Seizure Reduction Deepening Over Time Months with at least 10 contributing participants are shown. Data cutoff 14 August 2026. Month 5 (start of open-label period), n=67; Month 6, n=67; Month 7, n=66; Month 8, n=65; Month 9, n=61; Month 10, n=57; Month 11, n=54; Month 12, n=49; Mont
Slide 63: Significant Increase in Seizure-Free Days
63 Patients Experienced Significant Increase in Seizure-Free Days Source: Kamireddy et al. AES 2025; Bialer et al. Epilepsia 2026 Best-in-Disease Efficacy Seizure Freedom Functional Gains Well-Tolerated Patient Centric Days without a motor seizure Mean days per 28 days, 16-week double-blind period +
Slide 64: Gains Across Multiple Areas Beyond Seizures
64 Gains Observed Across Multiple Areas Beyond Seizures Source: Kamireddy et al. AES 2025; Bialer et al. Epilepsia 2026 Best-in-Disease Efficacy Seizure Freedom Functional Gains Well-Tolerated Patient Centric Participants improving by domain, last visit on relutrigine % of Cohort 2 participants, cli
Slide 65: Well Tolerated, No Drug-Related SAEs
65 Relutrigine Was Well Tolerated, With No Drug-Related SAEs No clinically significant findings in vital signs, laboratory results, physical exams or ECGs. AE=adverse event; ASM=antiseizure medication; ECG=electrocardiogram; SCB=sodium channel blocker; SAE=serious adverse event; TEAE=treatment-emerg
Slide 66: Patient-Friendly Dosing and Administration
66 Relutrigine Offers a Patient-Friendly Dosing and Administration Paradigm G/J tube=gastrostomy/gastrojejunostomy/jejunostomy tube. Best-in-Disease Efficacy Seizure Freedom Functional Gains Well-Tolerated Patient Centric Once Daily • One dose a day for patients and caregivers No Titration • No dose
Slide 67: Relutrigine Sets a New Bar in SCN2A/8A DEE
67 Relutrigine Sets a New Bar in SCN2A/8A DEE Across Every Dimension SAE=serious adverse event. Source: Kamireddy et al. AES 2025; Bialer et al. Epilepsia 2026 Best-in-Disease Efficacy -86% mean reduction at 18 months in the OLE Seizure Freedom 7 more motor seizure-free days than placebo in Cohort 2
Slide 68: What Positions Relutrigine for Efficacy in EMERALD?
68 What Positions Relutrigine for Efficacy in EMERALD? EMBOLD COMPLETED · POSITIVE P O P U L A T I O N SCN2A, SCN8A DEEs N a V C H A N N E L S Mutated EMERALD TOPLINE 4Q26 P O P U L A T I O N Broad DEEs >50 etiologies N a V C H A N N E L S Mostly normal The unique biophysical actions of relutrigine
Slide 69: Diverse DEE Genes Converge on the Common Output Stage
69 Diverse DEE Genes Converge on the Common Output Stage AIS, axon initial segment; DAPC, dynamic action-potential clamp; DEE, developmental and epileptic encephalopathy. Data: Berecki (Florey Institute) DAPC; AIS physiology: . RELUTRIGINE REDUCES NEURONAL FIRING IN WT NAV CHANNELS DAPC Firing evoke
Slide 70: Targeting Activity-Dependent Current
70 Targeting Activity-Dependent Current – Recovery from Fast Inactivation Praxis data on file. Berecki (Florey Institute) Yes, NaV availability falls ~25% at burst rates, but only ~3% at sparse 1–2 Hz firing RECOVERY FROM FAST INACTIVATION (WT NAV1.2) WHAT THAT MEANS FOR A FIRING NEURON CAN THE DRUG
Slide 71: Persistent Current Sustains Pathological Firing
71 Persistent Current Sustains Pathological Firing Whether or Not the Channel Is Mutated Praxis data on file. Berecki (Florey Institute) Abbreviations: INaP, persistent sodium current. No, a lower baseline current reaches the critical level with a smaller reduction V424L · INaP unaltered 89% AUC inh
Slide 72: EMERALD Population Spans the Entire DEE Spectrum
72 A Severe, Diverse Population Means EMERALD Results Will Apply Across the Entire DEE Spectrum ASM, antiseizure medication Baseline characteristics · median age 13 years HIGH, EARLY-ONSET SEIZURE BURDEN BROAD, REPRESENTATIVE ETIOLOGIES SIGNIFICANT FUNCTIONAL IMPAIRMENT 58 median motor seizures per
Slide 73: Relutrigine Commercialization Strategy
73 R E L U T R I G I N E Commercialization Strategy Erik Johnson
Slide 74: High-Touch, Specialized Execution Model
74 SCN2A and SCN8A Market Opportunity Demands a High-Touch, Specialized Execution Model M A R K E T D Y N A M I C S Ultra-rare disease Activated and engaged market among those diagnosed Caregivers and children Centers of excellence and specialized pediatric neurologists Single-specialty pharmacy dis
Slide 75: A Long and Complicated Journey Begins at Birth
75 For SCN2A and SCN8A Families, a Long and Complicated Journey Begins at Birth Data source: Internal claims data. Abbreviations: ASM, anti-seizure medication; DEE, developmental and epileptic encephalopathy; ER, emergency room INITIAL MANIFESTATION Early onset, rapid progression and developmental d
Slide 76: No Guidelines or Targeted Options in DEE
76 With No Guidelines or Targeted Options, DEE Seizures Persist Despite Aggressive Off-Label Polytherapy Quotes and ASM figures from HCP market research. Abbreviations: ASM, anti-seizure medication; CDKL5, CDKL5 deficiency disorder; LGS, Lennox-Gastaut syndrome; TSC, tuberous sclerosis complex T H E
Slide 77: HCPs Value Relutrigine Profile
77 HCPs Value Relutrigine Profile of Improved Efficacy and Quality of Life and Intend to Broadly Use it Data on File; Analysis is based on DEE Treaters from Quantitative Research conducted (N=128); Abbreviations: ASM: Anti-Seizure Medication; DEEs: Developmental and Epileptic Encephalopathies; HCP:
Slide 78: Hub Accelerates Relutrigine Access and Support
78 The Hub of the Future Accelerates Relutrigine Access and Delivers White-Glove Support for Every Family Abbreviations:; EHR, electronic health record. P R E S C R I P T I O N I N T A K E Praxis Horizons Digital Pharmacy • Receives e-Rx via EHR • Immediate text to patient/caregiver • Starts BI, PA
Slide 79: Relutrigine Pricing Strategy Balances Value With Access
79 • Launch pricing to maximize drug value without restricting access • Benchmarked to rare-disease analogs, led by SEPHIENCE as the latest launch • Other branded DEE drugs are widely recognized as significantly underpriced, making them not the most relevant comparators P R I C I N G P R I N C I P L
Slide 80: List Prices Held Steady as Labels Expanded
80 Precedents Show List Prices Held Steady Even as Labels Expanded to Populations up to 20x Larger than Launch Index = WAC (list price before rebates and discounts) per unit on the day before expansion approval = 100. Kalydeco → Trikafta indexed on cost per day of therapy at labeled adult dose, swit
Slide 81: Most SCN2A/8A Patients Are Invisible in Data
81 Most SCN2A/8A Patients Are Invisible in Data, Not to Our Field Team Each dot ≈ 100 patients. 1. GeneDx and Invitae genetic testing data tokenized to Komodo claims plus 2025 GeneDx results. 2. Sederman R, et al. AES 2022 Poster 1.409: 3. Diagnosis rate from Musante L, et al. Genes 2022. ~1.9K Visi
Slide 82: More Than 300K DEE Patients Lack Effective Treatment
82 Beyond SCN2A/8A, more Than 300K DEE Patients Still Lack Effective Treatment Each dot ≈ 100 patients, drawn to scale; SCN2A/8A ~10K (Musante L, et al. Genes 2022). Poke G, et al. Neurology 2023;100:e1363–e1375, Sederman R, et al. AES 2022 poster 1.409. DEE, developmental and epileptic encephalopat
Slide 83: SCN2A/SCN8A Supports a $1B Peak
83 SCN2A/SCN8A Alone Supports a $1B Peak, While Minimal Penetration into the Broad DEE Market Could Add Multi-Blockbuster Potential Each dot ≈ 100 patients. Illustrative; assumes $400K net annual price. I L L U S T R A T I V E P E A K S A L E S : 2,500 SCN2A/8A patients $1B 25% penetration of ~10K p
Slide 84: Relutrigine: Field Readiness
84 R E L U T R I G I N E Field Readiness for First SCN2A & SCN8A Targeted Therapy John Bullock
Slide 85: Deep Where Patients Concentrate, Broad Enough to Reach Everyone
85 Deep Where Patients Concentrate, Broad Enough to Reach Everyone 100% Coverage From Day 1 Abbreviations: HCO, healthcare organization; HCP, healthcare provider, Data based on Claims Data HCOs treating known & diagnosed SCN2A/8A patients Dots = HCOs with treating HCPs; shading = known patients by s
Slide 86: Prescribing Patterns Extend Reach
86 Prescribing Patterns Allow Us to Extend the Reach to HCPs Who Will Help Us Find Patients Source: Internal Claims Data. 52% of first ASM prescriptions come from pediatric neurologists ~75% of claims for branded ASMs are from pediatric neurologists 0% 2% 4% 8% 14% 19% 52% Genetics PCP Neurology Neu
Slide 87: Dedicated Field Team in Place
87 Dedicated Field Team in Place Ready to Activate and Engage Critical Stakeholders Sales Medical Affairs Patient Services Sizing Enables Full Coverage at Launch Enables the team to shift coverage as more patients are identified, without disruptive changes after launch Foundation ready to expand for
Slide 88: Field Team Has Reached Every Priority Account
88 Field Team Has Reached Every Priority Account Ahead of PDUFA 100% of top 10 accounts per territory 100% of Tier 1 and Tier 2 target HCPs As of today, the rare epilepsy field team has profiled: KEY INSIGHTS FROM ACCOUNT PROFILING SCN2A/8A and overall DEE patients under care confirmed EMR and presc
Slide 89: Favorable Access for Relutrigine
89 Clear Unmet Need and Pre-Qualified Patients Point to Favorable Access for Relutrigine A C C E S S L A N D S C A P E P A Y E R M I X ~45% Medicaid ~50% Commercial Prescribed by a specialist Trial of prior ASMs Diagnosis confirmation Reauthorization criteria P A Y E R A C C E S S S T R A T E GY Hig
Slide 90: Cerebrum Small Molecule Platform
90 CEREBRUM SMALL MOLECULE PLATFORM Cerebrum utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies
Slide 91: Building on the T-Type Calcium Channel MOA
91 Praxis Is Building on the T-Type Calcium Channel MOA on 3 Fronts Abbreviations: ASD, autism spectrum disorder; ET, essential tremor; PD, Parkinson’s disease; RLS, restless legs syndrome. T-TYPE CALCIUM CHANNEL 1 · NEW INDICATIONS Ulixacaltamide beyond ET Trials starting in PD, RLS and ASD 2 · NEX
Slide 92: Building on the T-Type Calcium Channel MOA
92 Praxis Is Building on the T-Type Calcium Channel MoA on 3 Fronts Abbreviations: ASD, autism spectrum disorder; ET, essential tremor; PD, Parkinson’s disease; RLS, restless legs syndrome. T-TYPE CALCIUM CHANNEL 1 · NEW INDICATIONS Ulixacaltamide beyond ET Trials starting in PD, RLS and ASD 2 · NEX
Slide 93: Ulixacaltamide Line Extensions: Four Large Populations
93 Ulixacaltamide Line Extensions: One Target, Four Large Populations With Significant Unmet Needs 1. Louis ED, Ottman R. How many people in the USA have essential tremor? Tremor Other Hyperkinet Mov (N Y). 2014;4:259. 2. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence
Slide 94: Potential to Fill Treatment Gaps in PD, RLS and ASD
94 Ulixacaltamide’s Potential to Fill Treatment Gaps in PD, RLS and ASD Source: Pasquini et al, 2023; Silber et al, 2026; Praxis data on file INDICATION CURRENT TREATMENT UNMET NEED ULIXACALTAMIDE COULD OFFER PD Parkinson's disease Levodopa and other dopaminergic drugs • Tremor often resists dopamin
Slide 95: T-Type Channels Set the Thalamus's Firing Mode
95 T-Type Channels Set the Thalamus's Firing Mode; When Gating Fails, Abnormal Bursts Reach the Cortex TTCC, T-type calcium channel. Spike trains are schematic, not recorded data. Matthews et al, 2023 THALAMUS Relays converging inputs to the cortex RELAY MODE Steady, faithful spikes BURST MODE Clust
Slide 96: Ulixacaltamide Blocks T-Type Channels at the Thalamus
96 Ulixacaltamide Blocks T-Type Channels at the Thalamus and at Each of Its Inputs Cav3, T-type calcium channel family; TRN, thalamic reticular nucleus. Spike trains are schematic, not recorded data. Cortex Thalamus Sensorimotor gating Thalamic reticular nucleus Cerebellum Movement timing Basal gang
Slide 97: Four Diseases, Four Circuits, One Common Target
97 Four Diseases, Four Circuits, One Common Target BGTC, basal ganglia–thalamocortical; CTC, cerebello-thalamo-cortical; DBS, deep brain stimulation; PLMS, periodic limb movements in sleep; STN, subthalamic nucleus; TRN, thalamic reticular nucleus; TTCC, T-type calcium channel; Vim, ventral intermed
Slide 98: Four Diseases, Four Circuits, One Common Target
98 Four Diseases, Four Circuits, One Common Target BGTC, basal ganglia–thalamocortical; CTC, cerebello-thalamo-cortical; DBS, deep brain stimulation; PLMS, periodic limb movements in sleep; STN, subthalamic nucleus; TRN, thalamic reticular nucleus; TTCC, T-type calcium channel; Vim, ventral intermed
Slide 99: Both PD Motor Circuits Pass Through Ulixacaltamide Targets
99 Both PD Motor Circuits Pass Through Ulixacaltamide Targets BGTC, basal ganglia–thalamocortical; CTC, cerebello-thalamo-cortical; DBS, deep brain stimulation; ET, essential tremor; GPi, globus pallidus internus; STN, subthalamic nucleus; Vim, ventral intermediate nucleus of the thalamus. Source: H
Slide 100: RLS Stems From Thalamic and Spinal Overexcitation
100 RLS Stems From Thalamic and Spinal Overexcitation DBS, deep brain stimulation; ET, essential tremor; GPi, globus pallidus internus; PLMS, periodic limb movements in sleep; STN, subthalamic nucleus; Vim, ventral intermediate nucleus. Source: Ferré et al, 2019; Clemens et al, 2006; Gorges et al, 2
Slide 101: Ulixacaltamide Reversed ASD-Like Behaviors in Mouse Models
101 Ulixacaltamide Reversed ASD-Like Behaviors in Three Mouse Models BTBR, inbred mouse strain with ASD-like behaviors; Cntnap2, contactin-associated protein-like 2 knockout; Scn2a, sodium channel gene variant model; TRN, thalamic reticular nucleus. Grooming: 10–12 mice per group; open-arm time (ele
Slide 102: PD Lowest-Risk Line Extension; RLS and ASD Larger Markets
102 PD Is the Lowest-Risk Line Extension; RLS and ASD Offer Larger Markets at Higher Risk Positioning is qualitative, based on internal assessment. Bubble area proportional to estimated US prevalence (RLS: moderate-to-severe).. Sources: Marras et al, 2018; Allen et al, 2005; Dietz et al, 2020; Pasqu
Slide 103: Building on the T-Type Calcium Channel MOA on 3 Fronts
103 Praxis Is Building on the T-Type Calcium Channel MOA on 3 Fronts Abbreviations: ASD, autism spectrum disorder; ET, essential tremor; PD, Parkinson’s disease; RLS, restless legs syndrome. T-TYPE CALCIUM CHANNEL 1 · NEW INDICATIONS Ulixacaltamide beyond ET Trials starting in PD, RLS and ASD 2 · NE
Slide 104: Next-Gen T-Type Calcium Channel Inhibitors
104 Next-Gen T-Type Calcium Channel Inhibitors Cav3.x, T-type voltage-gated calcium channel isoforms (Cav3.1, Cav3.2, Cav3.3) 1 · D I S C O V E R 2 · D E S I G N Pan-Cav3.x Block all three T-type isoforms Isoform-selective Target Cav3 isoforms 3 · D I F F E R E N T IA TE 2 molecules entering first-i
Slide 105: Next-Gen Molecules Show Distinct CaV3.x Profile
105 Next-Gen Molecules Show a Distinct CaV3.x Profile From Ulixacaltamide 10 100 1,000 ULIXACALTAMIDE PRAX-050 IC50, nM, log scale (lower = more potent) CaV3.1 CaV3.2 CaV3.3 Tonic block (TB) Voltage dependent block (VDB) ULIXACALTAMIDE Most potent at CaV3.1, with a wide gap between tonic and voltage
Slide 106: Building on the T-Type Calcium Channel MOA on 3 Fronts
106 Praxis Is Building on the T-Type Calcium Channel MOA on 3 Fronts Abbreviations: ASD, autism spectrum disorder; ET, essential tremor; PD, Parkinson’s disease; RLS, restless legs syndrome. T-TYPE CALCIUM CHANNEL 1 · NEW INDICATIONS Ulixacaltamide beyond ET Trials starting in PD, RLS and ASD 2 · NE
Slide 107: Novel Delivery Technology: Active Transdermal Patch
107 Novel Delivery Technology Could Improve Patient Access, Dosing and Adherence: Active, Transdermal Patch Collaboration with Remagine Labs. Regulatory path and timing subject to FDA engagement. Abbreviations: ET, essential tremor; PK, pharmacokinetic. Electronic Transdermal Drug Delivery System (e
Slide 108: Ulixa eTDDS Flux Data Support Therapeutic Exposure
108 Ulixa eTDDS Flux Data Support Therapeutic Ulixacaltamide Exposure CUMULATIVE DRUG PERMEATION Ulixacaltamide (µg/cm²) 0 4 8 12 16 20 24 Time (h) Current: mean, n=3, measured 0 to 6 h; dashed line projects to 24 h at the measured flux. V2 dotted line spans the 3 to 19 h sampling gap. ELECTRODE GEN
Slide 109: Simulated Patch Exposure Within Oral Dosing Concentration
109 Simulated Patch Exposure Sits Within Oral Dosing Concentration Model: oral PK parameters; patch input from in vitro porcine flux 0 1 2 3 4 5 6 7 Pl as m a co nc en tr at io n Time (days) Ulixa eTDDS Ulixa oral PEAK-TO-TROUGH RATIO 2.4× 1.0× Oral once daily Ulixa eTDDS patch
Slide 110: Timeline to Next Key Clinical Milestones
110 Building the Leading T-Type Ca Channel Franchise: Timeline to Next Key Clinical Milestones 2027 2028 2029 2030 1 · LINE EXTENSIONS PD Trial Readout RLS Trial Readout ASD Trial Readout 2 · NEXT-GEN MOLECULES PRAX-050 (Pan CaV3.x) FIH Data PRAX-051 (CaV3.x selective) FIH Data 3 · BETTER DELIVERY T
Slide 111: Cerebrum Epilepsy Pipeline
111 CEREBRUM Epilepsy Pipeline
Slide 112: KCNT1 Epilepsy Is Severe With No Approved Therapy
112 KCNT1 Epilepsy Is Severe and Has No Approved Therapy EIMFS: epilepsy of infancy with migrating focal seizures; SHE: sleep-related hypermotor epilepsy (formerly ADNFLE). Source: Gras et al., Brain Commun 2026; Bonardi et al., Brain 2021; Mathieu Kuchenbuch et al. Brain 2019. INFANT ONSET KCNT1-DE
Slide 113: PRAX-206 Preclinical Profile
113 PRAX-206 Is Potent, Selective and Well Tolerated in Preclinical Models, With First-in-Human Planned for 2027 Number of spontaneous seizures across 9 days (quantified 12 h post-dose each day) and nesting score on Day 9; 300 mg/kg PRAX-206. Acute panel: single dose. *p<0.05, **p<0.01, ****p<0.0001
Slide 114: Cerebrum Pain Pipeline
CEREBRUM™ Pain Pipeline PRAXIS 4
Slide 115: Why Pain: >150M US Patients With Unmet Need
115 Why Pain: >150M US Patients With a Significant Unmet Need Source: Baskozos et al (2023), BioSpace (2024), CDC, Cunningham et al (1984), Dalke Meucci et al (2015), DelveInsight (2024), DiBonaventura et al (2017), EvaluatePharma (2024), Freburger et al (2009), George et al (2024), Lopez et al (202
Slide 116: Pain Transmission Involves Multiple NaV Isoforms
116 Transmission of Pain Involves Multiple NaV Isoforms in Different Compartments PERIPHERAL NERVOUS SYSTEM Nerves in the skin, muscles and organs detect injury and fire the pain signal NaV1.7 NaV1.8 CENTRAL NERVOUS SYSTEM The brain and spinal cord relay the signal and process it into the perception
Slide 117: Differentiated Preclinical Development Framework
117 Designing a Wide Range of Molecules and Using a Differentiated Preclinical Development Framework to Pick the Best Candidates PAC-PAIN, Praxis Analysis of Concordance for Pain. PERIPHERAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM NaV1.2 NaV1.6 NaV1.7 NaV1.8 DATA-LED DECISION-MAKING 1 Pursue multiple
Slide 118: PAC-PAIN Develops Pain Model Cascades
118 PAC-PAIN Develops Pain Model Cascades for Each Indication to Reduce Translational Risk Acute Pain Neuropathic Pain Chronic Pain Inflammatory Pain M1 M2 M3 M4 M5 M6 M7 M8 M9 Acute Pain M1 M2 M3 M4 Neuropathic Pain M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 Post-op M1 Visceral M1 Osteoarthritis M1
Slide 119: Suzetrigine's Approval Validates Sodium Channel Targeting
119 Suzetrigine's Approval Clinically Validates Sodium Channel Targeting in Pain Illustrative. Suzetrigine (Journavx, Vertex), NaV, voltage-gated sodium channel. PERIPHERAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM NaV1.2 NaV1.6 NaV1.7 NaV1.8 SUZETRIGINE'S PROFILE CLINICALLY PROVEN Suzetrigine (Journavx
Slide 120: PRAX-215 Pairs Balanced Pan-NaV Potency
120 PRAX-215 Pairs Balanced Pan-NaV Potency With Praxis Functional State Selectivity Illustrative slider positions based on PRAX-215 IC50s. Model X, Y, Z: preclinical pain models. PERIPHERAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM NaV1.2 NaV1.6 NaV1.7 NaV1.8 PRAX-215 PROFILE PHASE 1 ONGOING PRAX-215 •
Slide 121: PRAX-110 Biased Toward NaV1.8
121 PRAX-110 Is Biased Toward NaV1.8 While Keeping Activity Across Other Pain Isoforms Illustrative slider positions. Praxis data on file. PERIPHERAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM NaV1.2 NaV1.6 NaV1.7 NaV1.8 PRAX-110 PROFILE IND SUBMISSION IN 2027 PRAX-110 Profile • Biased potency at NaV1.8,
Slide 122: NaV1.x Pain Franchise Development Milestones
122 NaV1.x Pain Franchise Development Milestones 2027 2028 2029 2030 215 · PAN-NaV Acute pain Chronic pain SAD / MAD Trial Readout Trial Readout 110 · NaV1.8-BIASED Acute pain Chronic pain IND SAD / MAD Trial Readout Trial Readout PAC-PAIN guides indication selection and preclinical model prioritiza
Slide 123: Solidus ASO Platform
123 SOLIDUS ASO PLATFORM Solidus is an efficient, targeted precision medicine discovery and development engine for ASOs anchored on a proprietary, computational methodology
Slide 124: Multiple Routes to Address Genetically Defined Disease
124 1 PIVOTAL-STAGE ANCHOR Elsunersen (PRAX-222) in the EMBRAVE3 registrational study N MULTIPLE RNA CONTROL MECHANISMS Silencing, splice switching, NAS suppression and other expression upregulation approaches 6 EARLY-STAGE TARGETS Focused programs across genetically defined CNS disorders REPEATABLE
Slide 125: Elsunersen Targets the Source of SCN2A Gain-of-Function Disease
125 Elsunersen (PRAX-222) Targets the Source of SCN2A Gain-of- Function Disease DISEASE BIOLOGY WITH ELSUNERSEN SCN2A GAIN-OF-FUNCTION Hyperactive NaV1.2 channels contribute to neuronal hyperexcitability and severe early-onset seizures. RNA-LEVEL INTERVENTION An RNase H1-active ASO reduces SCN2A mRN
Slide 126: EMBRAVE Part A Showed Marked Seizure Reduction
126 EMBRAVE Part A Showed Marked Seizure Reduction and Disease- Modifying Benefits, Earning it Breakthrough Therapy Designation Q4W: every 4 weeks; GOF: gain of function; DEE: developmental and epileptic encephalopathy; SAE: serious adverse event Source: ClinicalTrials.gov NCT05737784; Praxis data o
Slide 127: EMBRAVE3 Pivotal Single-arm Registrational Study
127 EMBRAVE3: Pivotal Single-arm Registrational Study with Expected 2027 Topline and NDA Filing Primary endpoint: % change in monthly motor seizure frequency from baseline. Q4W: every 4 weeks; DEE: developmental and epileptic encephalopathy; NDA: new drug application Source: ClinicalTrials.gov NCT07
Slide 128: Six Genetically Defined Targets Extend Solidus
128 Six Genetically Defined Targets Extend Solidus Beyond Elsunersen PRAX-080 PCDH19 Mosaic expression disorder MODALITY Gapmer / RNA silencing PRAX-090 SYNGAP1 Haploinsufficiency DEE MODALITY SYNGAP1 upregulation PRAX-100 SCN2A Loss-of-function neurodevelopmental disorder MODALITY SCN2A upregulatio
Slide 129: AI-guided ASO Discovery
129 AI-guided ASO Discovery: From Screening Data to Predictive Design 01 DESIGN Generate ASO candidates Use 5′UTR sequence and specificity filters to shortlist designs. 131 candidate 20-mers 22 filtered 02 MEASURE + LEARN Train predictive models Relate sequence features to measured gene upregulation
Slide 130: The Platform Opportunity: Repeatable Advancement of RNA Programs
130 The Platform Opportunity Is Disciplined, Repeatable Advancement of RNA Programs 1 GENETIC INSIGHT Causal variant and direction of dysfunction 2 MECHANISM MATCH Silence, splice or increase expression 3 ASO DESIGN Sequence and chemistry optimization 4 TRANSLATIONAL PROOF RNA/protein, functional re
Slide 131: Praxis' Full Pipeline Today
131 Praxis’ Full Pipeline Today DEE: developmental and epileptic encephalopathy; FOS: focal onset seizures; LoF: loss of function; ATM: Ataxia-telangiectasia. MARKETED C E R E B R U M S O L ID U S Essential tremor Ulixacaltamide Parkinson's disease PRAX-051 CaV3.x-selective inhibitor PRAX-050 Pan-Ca
Slide 132: Dare For More
Praxis Precision Medicines — Investor Day (November 2026) on 6ix